Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles

2019 
Triglyceride elevation has re-emerged as a potent marker of residual cardiovascular risk in statin-treated patients [(1)][1]. Converging lines of evidence from epidemiological analyses, Mendelian randomization studies, and outcome data from REDUCE-IT (Reduction of Cardiovascular Events with EPA-
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    6
    References
    48
    Citations
    NaN
    KQI
    []